Brokerages remain optimistic on a select set of companies across sectors such as renewable energy, healthcare, real estate, and manufacturing, citing strong growth visibility, improving business fundamentals, and sectoral tailwinds.We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Brokerage Recommendations
Brokerages remain optimistic on a select set of companies across sectors such as renewable energy, healthcare, real estate, and manufacturing, citing strong growth visibility, improving business fundamentals, and sectoral tailwinds.
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Motilal Oswal on Shaily Engineering Plastics: Buy| Target Rs 3404| LTP Rs 2695| Potential Upside 26%
Motilal Oswal Financial Services has maintained a Buy rating on Shaily Engineering Plastics with a target price of Rs 3,404, indicating a potential upside of around 26% from the current market price of Rs 2,695.
Motilal Oswal on Suzlon Energy: Buy| Target Rs 65| LTP Rs 54| Potential Upside 20%
Motilal Oswal Financial Services has assigned a Buy rating to Suzlon Energy with a target price of Rs 65, implying a potential upside of nearly 20% from the current market price of Rs 54.
Choice Institutional Equities on Fortis Healthcare Ltd: Buy| Target Rs 1140| LTP Rs 970| Potential Upside 17%
Choice Institutional Equities has recommended a Buy rating on Fortis Healthcare with a target price of Rs 1,140, suggesting a potential upside of around 17% from the current market price of Rs 970.
Emkay Global on Mahindra Lifespace Developers: Buy| Target Rs 460| LTP Rs 338| Potential Upside 36%
Emkay Global has reiterated a Buy rating on Mahindra Lifespace Developers with a target price of Rs 460, which implies a potential upside of approximately 36% from the current market price of Rs 338.
Emkay Global on Rainbow Children’s Medicare: Buy| Target Rs 1550| LTP Rs 1350| Potential Upside 14%
Emkay Global has maintained a Buy recommendation on Rainbow Children's Medicare with a target price of Rs 1,550, indicating a potential upside of about 14% from the current market price of Rs 1,350.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)